FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286297779> ?p ?o ?g. }

• W4286297779 endingPage "7032" @default.
• W4286297779 startingPage "7032" @default.
• W4286297779 abstract "7032 Background: Enasidenib (ENA) is an oral inhibitor of mutant-IDH2 (mIDH2) proteins. In the phase 3 IDHENTIFY trial, ENA improved event-free survival (EFS), overall response, and complete remission rate vs conventional care regimens (CCR) ( P < 0.01 for all) in patients (pts) ≥ 60 years of age with m IDH2 R/R AML with 2 or 3 prior treatments (Tx) (DiNardo 2021). Pt-reported HRQoL was a secondary trial endpoint. Methods: IDHENTIFY is an open-label, randomized trial (NCT02577406). Pts were preselected to a CCR (SC azacitidine, intermediate- or low-dose Ara-C, or supportive care) and then randomized 1:1 to ENA 100 mg/d or CCR in 28-d cycles. Key HRQoL endpoints were mean changes from baseline (CFB) overall and by clinical response in the Global Health Status/QoL, Physical Functioning, Role Functioning, Fatigue, and Dyspnea domains of the EORTC QLQ-C30 questionnaire, and in EQ-5D-5L utility index (UI) and visual analogue scale scores. The QLQ-C30 and EQ-5D-5L were assessed on D1 of each Tx cycle (C) and at end of Tx. Minimally important differences (MIDs) in CFB scores within or between Tx arms were based on accepted thresholds. Sensitivity analysis using imputed data on CFB was conducted using pattern mixture modeling. Results: HRQoL-evaluable cohorts included 118/158 (74.7%) pts in the ENA arm and 80/161 (49.7%) in the CCR arm; 40 ENA pts and 81 CCR pts were not evaluable due to missing data at baseline (BL; 22 ENA and 51 CCR) and/or at ≥1 post-BL visit (26 ENA and 69 CCR). Pts ineligible for HRQoL analyses had lower response rates and worse EFS and overall survival than HRQoL-evaluable pts. Overall QLQ-C30 completion rates in the ENA and CCR arms were 79% and 65%, respectively ( P < 0.001). While there was no meaningful improvement or worsening from BL (ie, exceeding MID) within either Tx arm in the key QLQ-C30 domains, scores worsened during initial Tx cycles and then improved with continued Tx. Mean EQ-5D-5L scores also worsened during early cycles in both Tx arms, with meaningful UI deterioration in the ENA arm from C2 through C7. However, between-group comparisons showed no consistent differences between ENA and CCR in mean CFB. Sensitivity analysis with imputation of missing CFB data showed worsened HRQoL compared with non-imputed data in the CCR arm but not with ENA. In the ENA arm, clinical responders reported relatively stable mean HRQoL scores over time, and non-responders showed no meaningful differences in CFB vs the CCR arm. Conclusions: HRQoL measures tended to worsen during early cycles in both Tx arms and gradually improved with continued Tx. Data should be interpreted with caution as only approximately one-half of pts in the CCR arm were HRQoL-evaluable. ENA improved clinical efficacy measures vs CCR without compromising HRQoL in older pts with R/R AML. Clinical trial information: NCT02577406." @default.
• W4286297779 created "2022-07-21" @default.
• W4286297779 creator A5001293238 @default.
• W4286297779 creator A5002489867 @default.
• W4286297779 creator A5003682435 @default.
• W4286297779 creator A5005591514 @default.
• W4286297779 creator A5010786159 @default.
• W4286297779 creator A5017435311 @default.
• W4286297779 creator A5041974040 @default.
• W4286297779 creator A5042611019 @default.
• W4286297779 creator A5044624520 @default.
• W4286297779 creator A5059990105 @default.
• W4286297779 creator A5063657535 @default.
• W4286297779 creator A5067521829 @default.
• W4286297779 creator A5075397421 @default.
• W4286297779 creator A5076389889 @default.
• W4286297779 creator A5077284234 @default.
• W4286297779 creator A5080658538 @default.
• W4286297779 creator A5085943321 @default.
• W4286297779 date "2022-06-01" @default.
• W4286297779 modified "2023-09-27" @default.
• W4286297779 title "Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-<i>IDH2</i> relapsed or refractory acute myeloid leukemia (R/R AML)." @default.
• W4286297779 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.7032" @default.
• W4286297779 hasPublicationYear "2022" @default.
• W4286297779 type Work @default.
• W4286297779 citedByCount "0" @default.
• W4286297779 crossrefType "journal-article" @default.
• W4286297779 hasAuthorship W4286297779A5001293238 @default.
• W4286297779 hasAuthorship W4286297779A5002489867 @default.
• W4286297779 hasAuthorship W4286297779A5003682435 @default.
• W4286297779 hasAuthorship W4286297779A5005591514 @default.
• W4286297779 hasAuthorship W4286297779A5010786159 @default.
• W4286297779 hasAuthorship W4286297779A5017435311 @default.
• W4286297779 hasAuthorship W4286297779A5041974040 @default.
• W4286297779 hasAuthorship W4286297779A5042611019 @default.
• W4286297779 hasAuthorship W4286297779A5044624520 @default.
• W4286297779 hasAuthorship W4286297779A5059990105 @default.
• W4286297779 hasAuthorship W4286297779A5063657535 @default.
• W4286297779 hasAuthorship W4286297779A5067521829 @default.
• W4286297779 hasAuthorship W4286297779A5075397421 @default.
• W4286297779 hasAuthorship W4286297779A5076389889 @default.
• W4286297779 hasAuthorship W4286297779A5077284234 @default.
• W4286297779 hasAuthorship W4286297779A5080658538 @default.
• W4286297779 hasAuthorship W4286297779A5085943321 @default.
• W4286297779 hasConcept C104317684 @default.
• W4286297779 hasConcept C121332964 @default.
• W4286297779 hasConcept C126322002 @default.
• W4286297779 hasConcept C127848430 @default.
• W4286297779 hasConcept C142424586 @default.
• W4286297779 hasConcept C143065580 @default.
• W4286297779 hasConcept C143998085 @default.
• W4286297779 hasConcept C159110408 @default.
• W4286297779 hasConcept C168563851 @default.
• W4286297779 hasConcept C185592680 @default.
• W4286297779 hasConcept C203092338 @default.
• W4286297779 hasConcept C2776059313 @default.
• W4286297779 hasConcept C2779951463 @default.
• W4286297779 hasConcept C535046627 @default.
• W4286297779 hasConcept C55493867 @default.
• W4286297779 hasConcept C71924100 @default.
• W4286297779 hasConcept C87355193 @default.
• W4286297779 hasConcept C90924648 @default.
• W4286297779 hasConceptScore W4286297779C104317684 @default.
• W4286297779 hasConceptScore W4286297779C121332964 @default.
• W4286297779 hasConceptScore W4286297779C126322002 @default.
• W4286297779 hasConceptScore W4286297779C127848430 @default.
• W4286297779 hasConceptScore W4286297779C142424586 @default.
• W4286297779 hasConceptScore W4286297779C143065580 @default.
• W4286297779 hasConceptScore W4286297779C143998085 @default.
• W4286297779 hasConceptScore W4286297779C159110408 @default.
• W4286297779 hasConceptScore W4286297779C168563851 @default.
• W4286297779 hasConceptScore W4286297779C185592680 @default.
• W4286297779 hasConceptScore W4286297779C203092338 @default.
• W4286297779 hasConceptScore W4286297779C2776059313 @default.
• W4286297779 hasConceptScore W4286297779C2779951463 @default.
• W4286297779 hasConceptScore W4286297779C535046627 @default.
• W4286297779 hasConceptScore W4286297779C55493867 @default.
• W4286297779 hasConceptScore W4286297779C71924100 @default.
• W4286297779 hasConceptScore W4286297779C87355193 @default.
• W4286297779 hasConceptScore W4286297779C90924648 @default.
• W4286297779 hasIssue "16_suppl" @default.
• W4286297779 hasLocation W42862977791 @default.
• W4286297779 hasOpenAccess W4286297779 @default.
• W4286297779 hasPrimaryLocation W42862977791 @default.
• W4286297779 hasRelatedWork W1608269846 @default.
• W4286297779 hasRelatedWork W2136206458 @default.
• W4286297779 hasRelatedWork W2887282919 @default.
• W4286297779 hasRelatedWork W2899353411 @default.
• W4286297779 hasRelatedWork W2955643247 @default.
• W4286297779 hasRelatedWork W2959603226 @default.
• W4286297779 hasRelatedWork W2980596691 @default.
• W4286297779 hasRelatedWork W2998951754 @default.
• W4286297779 hasRelatedWork W3089163820 @default.
• W4286297779 hasRelatedWork W3163371109 @default.
• W4286297779 hasVolume "40" @default.
• W4286297779 isParatext "false" @default.
• W4286297779 isRetracted "false" @default.
• W4286297779 workType "article" @default.